Skip to main content

Table 1 Patient characteristics

From: Echocardiographic assessment of diastolic dysfunction in elderly patients with severe aortic stenosis before and after aortic valve replacement

  TAVR SAVR P-value
n (%) or mean ± SD n (%) or mean ± SD
n 98 71  
Male 48 (49) 40 (56) 0.345
Age (y) 83 ± 5 78 ± 5 < 0.0001
BMI (kg/m2) 26 ± 5 27 ± 4 0.018
EF (%) 52 ± 13 55 ± 12 0.122
COPD 34 (35) 14 (20) 0.030
Cancer 20 (21) 15 (21) 0.480
Cerebrovascular disease 22 (22) 8 (11) 0.060
GFR pre (ml/min/1,73m2) 33 ± 12 38 ± 12 0.002
GFR post (ml/min/1,73m2) 35 ± 14 42 ± 17 0.001
PVD 32(33) 4 (6) 0.001
Hypertension 68 (70) 51 (72) 0.731
Diabetes 28 (29) 17 (24) 0.545
Smoking 13 (13) 8 (11) 0.698
Cholesterol (mmol/L) 4.7 ± 1.2 4.9 ± 1.1 0.322
PAP 40 ± 14 33 ± 10 0.001
CAD 69 (70) 42 (59) 0.323
Previous CABG 32 (33) 1 (1) < 0.0001
New CABG 0 (0) 31 (44) < 0.0001
Previous PCI 48 (49) 13 (18) 0.002
Pacemaker 13 (13) 5 (7) 0.252
LBBB 11 (11) 6 (9) 0.554
Heart failure < 2 weeks 80 (82) 43 (61) 0.002
CK MB post (U/L) 19 ± 58 28 ± 20 0.224
NT-proBNP (ng/L) 5416 ± 7920 1422 ± 2341 < 0.0001
NYHA III-IV pre 88 (89) 50 (70) 0.002
NYHA III-IV post 4 (6) 2 (3) 0.210
LogEuroScore 25 ± 13 10 ± 6 < 0.0001
  1. BMI Body mass index, CABG Coronary artery bypass grafting, CAD Coronary artery disease, CK Creatine kinase, COPD Chronic obstructive pulmonary disease, EF Ejection fraction, GFR Glomerular filtration rate, LBBB Left bundle brunch blocks, LogEuroScore Logarithmic European System for Cardiac Operative Risk Evaluation, NT-proBNP N-terminal prohormone of brain natriuretic peptide, NYHA New York Heart Association, PAP Pulmonary artery pressure, PCI Percutaneous coronary intention, PVD Peripheral vascular disease, SAVR Surgical aortic valve replacement, TAVR Transcatheter aortic valve replacement